["{\n\"step_by_step_thinking\": \"The article [Non-steroidal anti-inflammatory agent, phase I clinical trial with CN-100--single and repeated oral administration study] discusses the pharmacokinetic and safety studies of CN-100. The study involved 12 healthy male volunteers who received single or repetitive doses of CN-100. No notable adverse effects were observed, and the results concluded that CN-100 is evaluable for phase II testing.\",\n\"answer_choice\": \"A\"\n}"]